Newsfile Corp. Newsfile Corp
Phoenix, Arizona–(Newsfile Corp. – September 12, 2019) – The Stock Day Podcast welcomed FSD Pharma (OTCQB: FSDDF) (“the Company”), a company focused on the research and development of novel cannabinoid-based treatments for several central nervous system disorders including chronic pain, fibromyalgia and irritable bowel syndrome, and on the development of the highest quality indoor grown, pharmaceutical-grade cannabis. CEO Dr. Raza Bokhari joined Stock Day host Everett Jolly.
Dr. Bokhari began the interview by sharing some background information about the Company. “We are a licensed grower of indoor grown, medicinal-grade cannabis,” stated Dr. Bokhari. He further explained that the Company’s facility is located outside of Toronto, which is quickly expanding to become the largest indoor grow facility of its kind. In addition to this business sector, the Company also has a strong focus on the research and development of numerous cannabinoid pain treatments.
Dr. Bokhari also shared that the Company has recently acquired Prismic Pharmaceuticals, which will allow them to advance their treatment for fibromyalgia. “We’re very excited about that effort,” said Dr. Bokhari.
Jolly then asked about the Company’s upcoming revenue sources. Dr. Bokhari explained that the Company received its full Sale for Medical Purposes license on June 21, 2019. “That initiated a formal sales process for us,” shared Dr. Bokhari, adding that the Company also has a cultivation license, as well as processing license and medicinal-grade sales license.
Dr. Bokhari also shared that another recent acquisition made by the Company has expanded their distribution channels to Europe, particularly in Germany. “We’re hopeful that this will translate into better revenue lines for us,” explained Dr. Bokhari.
The Company has also secured another major revenue source by handling the processing of other licensed producers. He explained that some growers may not have such capabilities, representing a substantial opportunity for the Company.
Dr. Bokhari further explained that the Company has applied for a license extension to sell extended release gel capsules. This application will likely be finalized by the end of the year and could add significant value to the Company’s revenues.
Jolly then noted that the Company recently raised funding for its bioscience division and asked about their plans for this business sector. Dr. Bokhari explained that when the Company went public in May of 2018, they were able to raise $53 million. Now the Company is looking to raise an additional $5 million in an effort to support their bioscience division for the advancement of their research and development of cannabinoid compounds and their role in the treatment of numerous illnesses.
To close the interview, Dr. Bokhari thanked his shareholders for their support and encouraged interested listeners to keep up-to-date on the Company’s current projects. “We’re doubling down and investing further. We believe in the fundamentals of our company,” stated Dr. Bokhari.
To hear Dr. Raza Bokhari entire interview, follow the link to the podcast here: https://audioboom.com/posts/7365874-fsd-pharma-joins-the-stock-day-podcast-to-discuss-their-expanding-revenue-potential
About FSD Pharma
FSD Pharma is focused on the research and development of novel cannabinoid-based treatments for several central nervous system disorders including chronic pain, fibromyalgia and irritable bowel syndrome, and on the development of the highest quality indoor grown, pharmaceutical-grade cannabis. The Company is licensed to cultivate cannabis in approximately 25,000 square feet.
FSD’s wholly-owned subsidiary, FV Pharma, is a licensed producer under the Cannabis Act and Regulations, having received its cultivation license on October 13, 2017 and its full Sale for Medical Purposes license on June 21, 2019 . FV Pharma intends to cover all aspects of the cannabis industry, including cultivation, legal, processing, manufacturing, extracts and research and development.
Neither the Canadian Securities Exchange nor its regulation services provider accept responsibility for the adequacy or accuracy of this release.
Certain statements contained in this press release, including statements relating to the Private Placement and the expected size and closing thereof, constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on FSD Pharma’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. Actual results and developments may differ materially from those contemplated by these. The forward-looking information contained in this press release is made as of the date hereof, and FSD Pharma is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.
About The “Stock Day” Podcast
Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.
Stock Day Media
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/47746